Avantis US Small Cap Value ETF vs Twist Bioscience Corp — how do they compare? Avantis US Small Cap Value ETF trades at $124.32, while Twist Bioscience Corp trades at $91.7 (market cap $5.77B). The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals.
| AVUV | TWST | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $124.94 | $102.88 |
52-Week Low | $90.37 | $24.16 |
Market Cap | — | $5.77B |
Enterprise Value | — | $5.69B |
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $123.97, up 0.02% on the day, with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. small-cap value stocks, which have outperformed growth peers in 2026, driven by shifting rate expectations. Recent news highlights its role in diversifying tech-heavy portfolios and capturing the small-cap value premium.
Outlook remains positive as small-cap value gains favor amid economic shifts, though risks include higher volatility and sensitivity to interest rates. The fund offers growth potential but requires tolerance for the inherent risks of smaller companies.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Trailing returns across standard periods
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →